August 24, 2020
The Ministry of Health, Labor and Welfare (MHLW) on August 21 approved additional indications and dosages for a batch of medicines including MSD’s PD-1 inhibitor Keytruda (pembrolizumab) for esophageal cancer and AstraZeneca’s anti-PD-L1 antibody Imfinzi (durvalumab) for small cell lung...read more